Deadly fungus and companies with potential treatment

  • 📰 FoxBusiness
  • ⏱ Reading Time:
  • 28 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 53%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

The U.S. Food and Drug Administration approved Cidara Therapeutics and Melinta Therapeutics' antifungal drug for patients with little to no other options.

Novavax President and CEO Stanley Erck says the recently CDC-approved vaccine has shown great efficacy and is a 'bit more stable' than other immunizations on 'Cavuto: Coast to Coast.'to help patients with limited or no other treatment options.What is Rezzayo?

Both of these infections can be caused by a number of Candida species, including Candida auris , which started to spread at an alarming rate across U.S. health care facilities in the early days of the COVID-19 pandemic. Although Rezzayo was only approved for adults with limited or no alternative treatment options, its approval marked a major medical milestone, according to Cidara CEO Jeffrey Stein.

Candida auris is a yeast responsible for many infections. Resistant to most antifungal drugs, this fungus causes several deaths worldwide.

 

コメントありがとうございます。コメントは審査後に公開されます。

Not buying this fear mongering.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 458. in JP

日本 最新ニュース, 日本 見出し